This suggests that therapeutic strategies targeting HBx and aiming at restoring SMC5/6 function in HBV-infected hepatocytes may reduce the progression of hepatitis B, and that the combinations of IFN with bulevirtid could contribute to cure CHB infections [109]. Here, IFNA1 is linked to hepatitis B virus infection.